lymphoid cells

[Blood Cancer Journal] The authors evaluated the safety and immunogenicity of BNT162b2 vaccine in patients with hematological malignancies.

[Bone Marrow Transplantation] The authors evaluated the outcome of recipients of alternative donor allogeneic stem cell transplantation for T-cell lymphoma.

[Journal of Gastrointestinal Cancer] Biopsy revealed a lymphoma with strong expression of ALK (granular cytoplasmic), CD138, MUM1, kappa, moderate expression of CD45 and focal expression of CD20, CD79a and PAX5 and lack of expression of CD5, CD3, CD45RO, BCL6, CD10 and EMA.

[NPJ Vaccines] Scientists demonstrated that a liver stage-specific autophagy mutant of Plasmodium berghei, when used as a live vaccine under a chemoprophylaxis vaccination (CVac) regimen, provided superior long-lasting protection, in both inbred and outbred mice, as compared to WT-CVac.

[NexImmune, Inc.] NexImmune, Inc. announced a collaboration with Yale University’s Department of Immunobiology. The collaboration will focus on the use of NexImmune’s direct injection, artificial antigen presenting cells with regards to the regulation of autoimmune diabetes (Type 1 diabetes). Dr. Kevan Herold, Deputy Director of Yale Center for Clinical Investigation and Co-Director of the Yale Diabetes Center will be the principal investigator.

[Portage Biotech Inc.] Portage Biotech Inc., announced that the first patient has been dosed in the Oxford-led IMP-MEL study, a Phase I/II, open-label, dose-escalation and randomized expansion clinical trial assessing the safety, tolerability and efficacy of PORT-2, a liposome formulation of the invariant natural killer T-cell agonist IMM60 developed for the treatment of solid tumors.